Calcium Channel Blocker Market Trends, Share, Growth, Value, Analysis | Business Review, Key Findings, Developing Technologies
Luton, Bedfordshire, United Kingdom, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Calcium Channel Blocker Market.
The Calcium Channel Blocker Market is projected to register a CAGR of 5.3 % during the forecast period, to reach a valuation of USD 20.15 Billion by 2029.
There are short-acting and long-acting calcium channel blockers. Compared to long acting calcium channel blockers, short acting medications have a quicker reaction. The calcium channel blocker drug class includes Amlodipine (Norvasc), Diltiazem (Cardizem, Tiazac, and others), Felodipine, Isradipine, and Nicardipine. These medications are used to treat coronary artery disease, angina, irregular heartbeats (arrhythmia), and blood vessel conditions like Raynaud's disease.
Calcium channel blockers, also known as calcium antagonists, are prescription medications that are frequently used to treat blood diseases, particularly circulatory illnesses, as well as cardiac conditions including excessive blood pressure, angina, and arrhythmias. These inhibitors function by obstructing voltage-gated calcium channels, which in turn limits calcium entry into cardiac and smooth muscle cells.
Get Access to sample Report Pages: -
https://www.pharmaresearchconsulting.com/reports/calcium-channel-blocker-market-growth-trends-and-forecast-2022-2029-by-drug-class-dihydropyridine-benzothizepine-phenylalkylamine-distribution-channel-hospital-pharmacies-retail-pharmacies-others-and-by-regions/inquiry
Calcium Channel Blocker Market: Opportunities
Increased Government Initiatives and Clinical Studies
Growing public awareness of channel blockers and research projects being undertaken by public and private organisations to better understand these blockers are predicted to propel industry expansion.
Demand for Retail Pharmacies is Growing
Opportunities for market expansion are created by the increase in calcium channel blockers being prescribed by retail pharmacies and the rise in the number of retail pharmacies in developed nations. Additionally, because retail pharmacies are more convenient for customers to reach, patients prefer them for medicine purchases.
Calcium Channel Blocker Market: Recent Development
The American Food and Drug Administration (FDA) granted provisional permission in May 2022 for Zydus Worldwide DMCC's subsidiary to commercialise Selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults.
The FDA approved Norliqva (amlodipine) oral solution in February 2022 to treat hypertension in adults and children aged 6 and older, as well as to prevent coronary artery disease.
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Drug Class, Distribution Channel, Region
North America; Europe; China; Asia; Pacific; Central & South America; MEA
U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Poland; Spain; India; Japan; Thailand; Malaysia; Indonesia; Vietnam; Singapore; Philippines; Brazil; Argentina; Saudi Arabia; UAE; Oman
Pfizer Inc, Alvogen, AstraZeneca, Abbvie Inc, Exela, Pharma Sciences, LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, Arbor Pharmaceuticals LLC, Others.
Calcium Channel Blocker Market Key Players
Calcium Channel Blocker Market Major Key Players include: - Pfizer Inc, Alvogen, AstraZeneca, Abbvie Inc, Exela, Pharma Sciences, LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, Arbor Pharmaceuticals LLC, Others.
Browse Complete Premium Report for Calcium Channel Blocker Market: https://www.pharmaresearchconsulting.com/reports/calcium-channel-blocker-market-growth-trends-and-forecast-2022-2029-by-drug-class-dihydropyridine-benzothizepine-phenylalkylamine-distribution-channel-hospital-pharmacies-retail-pharmacies-others-and-by-regions
Global Calcium Channel Blocker Market Dynamics
The market for calcium channel blockers is anticipated to expand quickly due to the rise in heart diseases. Obesity, an unhealthy lifestyle, junk food, and overeating are just a few of the factors contributing to the rise in cardiovascular disease (CVD), artery blockage, arrhythmias, and circulatory disorders.
The leading cause of death nationwide in 2017 was coronary heart disease, which claimed over 365,914 lives. Due to the increasing prevalence of cardiovascular illness worldwide, industry companies are investing enormous sums of money to create novel therapies and remain competitive. Additionally, pharmaceutical industry firms are concentrating on developing novel medication combinations to increase accuracy while reducing drug or medicine intake.
Pharmaceuticals like Ecosprin AV 75 pill, for example, combine two medications and are intended to prevent heart attack and stroke. This pill lowers levels of LDL, or "bad," cholesterol, including triglycerides, and boosts levels of HDL, or "good," cholesterol, in the body while also preventing blood clots from forming. Hence amalgamation of medicines by the market players is likely to boost the growth of the market.
Increase in Cardiovascular Diseases as Drivers
The WHO estimates that between 60% and 85% of people lead sedentary lives. Only one out of every four Americans fulfils the recommended levels of physical activity, according to the CDC, who estimates that 31 million individuals over the age of 50 lead sedentary lifestyles. This accelerates market expansion.
Oral medications are predicted to accelerate market expansion. Given that the majority of medications are accessible in capsule and tablet form and that this is a highly practical mode of administration, the category is anticipated to accelerate the worldwide market.
The expansion of the worldwide calcium channel blocker market over the forecast period may be restrained by a shortage of competent employees who are unable to treat patients with these medications.
The high cost of these agents undoubtedly inhibits market expansion.
Calcium Channel Blocker Market: Segmentation
By Drug Class, it is segmented into
By Distribution Channel it is segmented into
Calcium Channel Blocker Market: Regional Analysis
Due to the high incidence of poison cases and increase in research and development for antidotes, North America has seen good growth for the global calcium channel blocker market over the anticipated period. Due to its expanding healthcare infrastructure, substantial number of generic manufacturers, growing number of government initiatives, and specialised communities, Asia-Pacific dominates the industry.
COVID-19 Impact on Global Calcium Channel Blocker Market
Given the current situation, COVID-19 has left a historically severe worldwide public health crisis that has affected almost every industry, and its long-term effects are anticipated to have an impact on industry growth throughout the course of the projected period. Clinical trial delays and the transition of healthcare infrastructure to manage COVID-19 have resulted in the termination of medication launches.
Due to the demand for a COVID-19 vaccine and treatment medications in the post-pandemic era, it is anticipated that the biotechnology and pharmaceutical sectors would see tremendous growth in the coming years. As a result, this will have a big effect on calcium channel blocker sales.
Browse More Pharmaceutical Market Reports:
Hard capsules are dosage forms that can be solid or semi-solid and can include liquid, gaseous, powdered, or pasty materials within. These tablets are made of cellulose derivatives, a protein called gelatin, and fat-rich ingredients like cocoa butter.
https://www.pharmaresearchconsulting.com/reports/hard-capsules-market-global-growth-trends-and-forecast-2022-2029-by-type-gelatin-based-hard-capsule-vegetarian-based-hard-capsule-application-oral-cosmetic-clinical-research-and-by-regions
The sodium chloride injection market has seen a significant alteration throughout the predicted time frame. The increasing middle class, consumer spending, and demand for health care are the main factors driving the market for sodium chloride injection.
https://www.pharmaresearchconsulting.com/reports/sodium-chloride-injection-market-growth-trends-and-forecast-2022-by-type-flexible-bag-plastic-bottles-glass-bottles-therapeutic-application-dehydration-generalized-weakness-end-user-hospitals-clinics-and-by-regions
Hemostasis And Tissue Sealing Agents Market
Hemostasis and Tissue Sealing Agents Market will register a CAGR of 8.5 % in revenue, and the global market size will reach USD 10 Billion by 2029.
https://www.pharmaresearchconsulting.com/reports/hemostasis-and-tissue-sealing-agents-market-global-growth-trends-and-forecast-2022-2029-by-product-topical-hemostat-adhesives-tissue-sealant-by-regions
UBS's Colin Bristow raised his rating on the stock to Buy from Neutral, saying Well Street's expectations for sales of Mounjaro are too low.
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
Less than five months after discouraging conversations with the U.S. Food and Drug Administration led Spero Therapeutics Inc. to pause work on a drug and lay off 110 people, the company is licensing that same drug to GSK plc for up to $291 million.
The 'wrongful death' suit could usher in a new threat for abortion providers and women nationwide
By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Financial Update On September 23, 2022, Virios Therapeutics, Inc. (NASDAQ:VIRI) announced the closing of a previously announced underwritten public offering of 10 million shares of common stock at a price of $0.50 per share. The company raised gross proceeds of $5.0 million before deducting underwriting discounts, commissions, and
Around one in five vaccinated Britons with Omicron or Delta strain experienced diarrhoea as a symptom
A respiratory virus that pops up every two years is causing an increase in pediatric hospitalizations in some parts of the country, according to the Centers for Disease Control and Prevention. The CDC said earlier this month that more children and teens tested positive for a type of enterovirus called EV-D68 in July and August of this year compared with the same two-month period in 2019, 2020 and 2021. It also said that hospitals in several U.S. regions had notified the agency in August about an increasing number of hospitalizations of pediatric patients who tested positive for rhinoviruses or enteroviruses.
AbbVie recently submitted a regulatory application in the European Union for Rinvoq to treat patients with a form of inflammatory bowel disease.
Shares of Bristol Myers Squibb (NYSE: BMY) were bouncing 3.4% higher as of 3:31 p.m. ET on Thursday after slipping a little earlier this week. Instead, today's move appeared to be the result of investors seeking relatively safe stocks as the Nasdaq Composite index and Russell 2000 small-cap index fell. Bristol Myers Squibb has seemed to be sort of a safe haven for investors throughout much of 2022.
The social media giant’s head of community operations apologised at the inquest into the teenager’s death on Thursday.
Shares of Spectrum Pharmaceuticals Inc. were down 22.0% in premarket trading on Friday, the day after a Food and Drug Administration committee voted 9-4 that the benefits of the company's experimental lung-cancer drug do not outweigh the risks. The FDA is not required to follow the committee's advice when deciding when to approve a new drug but often does. The regulator is expected to make its decision on or before Nov. 24. Spectrum on Friday also announced a five-year debt financing plan with S
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.
Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.
Harriet Corr, seven, is regaining her strength after enduring years of coughing fits and a weakened immune system
It is safe to get the newly formulated COVID-19 booster shot and the flu shot at the same time. SDI Productions/ E+ via Getty ImagesAt this point in the COVID-19 pandemic, nearly everyone has experienced the panic and uncertainty that come with having mild COVID-like symptoms – such as a cough and sore throat – only to test negative day after day. With cold and flu season just around the corner, that state of frustrating uncertainty is likely to strike most of us again. Both COVID-19 and the flu
Think Research Corporation (TSXV: THNK) ("Think" or the "Company"), a company focused on transforming healthcare through integrated digital health software solutions, today announced that it has granted 350,000 restricted share units (each, an "RSU") to key employees of the Company pursuant to the Company's Omnibus Equity Incentive Plan. 300,000 of the RSUs will vest in one year, and the remaining 50,000 RSUs will vest 1/3 on September 30, 2023, 1/3 on December 31, 2023 and 1/3 on December 31, 2
Updated COVID-19 boosters have gone into 4.4 million arms in the United States since a new revaccination campaign began three weeks ago, government data shows, a slower pace for the shots targeting the Omicron variant of the coronavirus than the rollout of the first boosters last year. Last year, when the United States initially authorized COVID boosters just for older and immunocompromised people, nearly 10 million received their third shot in the first three weeks. The latest data, released late on Thursday by the U.S. Centers for Disease Control and Prevention (CDC), did show increased interest in the Omicron shots over demand for the older boosters during the previous three weeks.